Michael Mollerus

Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…

Davis Polk advised an ad hoc group of holders of the unsecured notes and the first-lien notes of Jones Energy, Inc. in connection with Jones Energy’s comprehensive balance sheet…

Davis Polk advised the joint book-running managers in connection with the secondary offering of 15,000,000 shares of common stock of SolarWinds Corporation by certain of SolarWinds’…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Emerson Electric Co. of €500 million aggregate principal amount of 0.375% notes…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…

We advised Uniti Group on the sale to Phoenix Tower International

Davis Polk advised Aptiv PLC in connection with an SEC-registered offering of $300 million aggregate principal amount of its 4.350% senior notes due 2029 and $350 million aggregate…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk advised the administrative agent, joint lead arrangers, joint bookrunners and senior managing agents, with respect to The Dun & Bradstreet Corporation’s $2.53 billion senior…

Davis Polk is advising Morgan Stanley on its $900 million acquisition of Solium Capital Inc. The transaction is expected to close in the second quarter of 2019, subject to shareholder and…